Consiglio Nazionale delle Ricerche

The National Research Council (CNR) is the largest public research institution in Italy, with the mission of developing, diffusing, promoting research activities in the main fields of the knowledge, and studying their application for scientific, technological and economic progress of Italy. “Valorizzazione della Ricerca” Structure coordinates and manages CNR’s activities regarding research marketing, intellectual property protection and exploitation, setting up of new technological enterprises. The Structure relies on in-house expertise and acts in collaboration with the scientific network of Departments and Institutes, and with other offices of the Central Administration.

Piazzale Aldo Moro,7 - 00185, Roma

Cardio nanoparticles for administration of therapeutic products

managed by CNR


The technology refers to biocompatible, biodegradable, non-toxic, and bioresorbable nanoparticles for the delivery of therapeutic or diagnostic compounds to the heart.
The nanoparticles are characterized by a particular affinity for cardiac cells and can be administered via enteral and parenteral routes.
Being able to encapsulate and/or conjugate one or more therapeutic/diagnostic compounds, the nanoparticles can be used in the pharmaceutical industry for the delivery of therapeutic and/or diagnostic compounds to the heart for the treatment of acute or chronic pathological conditions.
The product of the present invention is also versatile and considered as a platform to be potentially used in other medical fields.


- Self-assembling and low cost production;
- High biocompatibility, biodegradability and non-toxicity;
- Versatile platform capable of conveying different types of therapeutic and/or diagnostic compounds (eg. nucleic acids, peptides, chemical compounds);
- Particularly akin internalization in cardiac cells;
- Potentially applicable for any use to other cellular districts;
- Compatible with the use of the cell-specific targeting molecules;


Total cardiac selectivity, which the team is currently work on


Heart failure, cardiac arrhythmia, diabetic cardiomyopathy, myocardial infarction, cardiac disease in general


Readiness Level (TRL)

technology validated in lab
"Delivery of therapeutic compound and efficient recovery of diabetic cardiomyopathy has been shown in vivo in a mouse model. Proof of concept of heart targeting has been shown in pigs"
(The pie chart refers to the entire portfolio contained in the database of the helpdesk)

Technology Readiness Levels (TRL) are a method of estimating technology maturity of Critical Technology Elements (CTE) of a program during the acquisition process. The use of TRLs enables consistent, uniform, discussions of technical maturity across different types of technology.

Patent Grading Report

Patent Grading Report

The Grading Patents Report evaluates and grades US patents

Sample Buy from Wisdomain


Current status

PCT Application


Available for



Catalucci Daniele, Miragoli Michele, Lafisco Michele, Tampieri Anna


Case manager: Alessia Naso

EU-Japan Centre
European CommissionMeti